News
Market and company headlines
DFTXAll
Loading
06:00Oct 211 Story
18:00Oct 191 Story
08:00-17:00Oct 132 Stories
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK, October 13, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 45,940 common shares of the Company (the "Options") with effective grant dates of October 13, 202
Definium Therapeutics: Outstanding Phase III Data De-Risks Pipeline, But Patience Required Ahead Of 2027
With $1.1 billion cash, Defunium Therapeutics is funded through 2030 but lacks near-term catalysts. Click for more on the DFTX stock.
11:00Oct 91 Story
16:00Sep 281 Story
02:00Sep 241 Story
11:00Sep 211 Story
12:00Sep 201 Story
19:00Sep 191 Story
10:00-22:00Sep 152 Stories
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
Large-cap healthcare outperformed this week: XLV gained 1.4% through Tuesday, while XBI fell 1.4% and IBB declined 0.5%.
Definium Reports Second Phase III Success in Anxiety Disorder Program
DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.
07:00-10:00Sep 152 Stories
Definium Therapeutics (DFTX) Stock May Trade At A Premium Despite Phase 3 DT120 Results
Definium Therapeutics has ridden a powerful three year run, and that surge now puts a spotlight on a simple question for investors who care about balance sheets. Is the current share price still grounded in what the business is worth on its books, or has sentiment pulled it away from its underlying equity value? Over the past three years, Definium Therapeutics has delivered a return of roughly 8.9x, which raises the stakes for whether the stock price still lines up with the value recorded on...
Definium tees up regulatory submission for psychedelic on Phase III hat trick
Definium Therapeutics plans to submit an NDA for DT120 in GAD In the first half of 2027.
05:00-07:00Sep 152 Stories
Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $78
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $64 to $78.
Why Definium Therapeutics (DFTX) Is Up 5.7% After Second Positive Phase 3 DT120 Anxiety Trial Result
Definium Therapeutics recently reported that its Phase 3 Panorama trial of DT120, an LSD-based orally disintegrating tablet, in adults with generalized anxiety disorder met the primary and all key secondary endpoints, with a single 100 µg dose delivering a statistically significant 5.1‑point placebo‑adjusted reduction in HAM‑A anxiety scores at Week 12. The data also showed early and durable symptom relief from just one treatment, with meaningful improvements as soon as Day 2 and no new...
03:00-08:00Sep 82 Stories
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
NEW YORK, September 08, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for DT120 (lysergide) ODT. The designation was supported by the significant unmet medical need in MDD and results from the Compa
Definium Therapeutics Receives FDA Breakthrough Therapy Designation For DT120 ODT; Second Breakthrough Therapy Designation For DT120 Reinforces Its Potential Across MDD And Generalized Anxiety Disorder
The designation was supported by the significant unmet medical need in MDD and results from the Company's Phase 3 Emerge study, in which a single 100 µg dose of DT120 ODT demonstrated a statistically significant
15:00Sep 41 Story
16:00Aug 311 Story
07:00Aug 261 Story
01:00-05:00Aug 182 Stories
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top analysts changed outlook on top names. See analyst ratings page for all changes.
B of A Securities Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $75
B of A Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Buy rating and announces Price Target of $75.
12:00Aug 141 Story
08:00-11:00Aug 132 Stories
Jones Trading Maintains Buy on Definium Therapeutics, Raises Price Target to $90
Jones Trading analyst Justin Walsh maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $74 to $90.
Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $64
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $58 to $64.
05:00-08:00Aug 132 Stories
RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $66
RBC Capital analyst Brian Abrahams maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $57 to $66.
Wells Fargo Maintains Overweight on Definium Therapeutics, Raises Price Target to $72
Wells Fargo analyst Benjamin Burnett maintains Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $68 to $72.
